Lymphocytosis and ibrutinib treatment of CLL

Davide Rossi; Gianluca Gaidano

doi:10.1182/blood-2014-01-549493

Lymphocytosis and ibrutinib treatment of CLL

Davide Rossi, Gianluca Gaidano

Dipartimento di Medicina Traslazionale

Risultato della ricerca: Contributo su rivista › Commento

Abstract

In this issue of Blood, Woyach et al clarify that prolonged lymphocytosis is composed of biologically inert leukemic cells and does not anticipate poor outcome or relapse. Prolonged lymphocytosis may be perceived as a failure of chronic lymphocytic leukemia (CLL) treatment with ibrutinib.

Lingua originale	Inglese
pagine (da-a)	1772-1774
Numero di pagine	3
Rivista	Blood
Volume	123
Numero di pubblicazione	12
DOI	https://doi.org/10.1182/blood-2014-01-549493
Stato di pubblicazione	Pubblicato - 20 mar 2014

Accesso al documento

10.1182/blood-2014-01-549493

Altri file e collegamenti

Link to publication in Scopus

Cita questo

@article{667afb87d07e4fc1ad60e40efb4d8e60,

title = "Lymphocytosis and ibrutinib treatment of CLL",

abstract = "In this issue of Blood, Woyach et al clarify that prolonged lymphocytosis is composed of biologically inert leukemic cells and does not anticipate poor outcome or relapse. Prolonged lymphocytosis may be perceived as a failure of chronic lymphocytic leukemia (CLL) treatment with ibrutinib.",

author = "Davide Rossi and Gianluca Gaidano",

year = "2014",

month = mar,

day = "20",

doi = "10.1182/blood-2014-01-549493",

language = "English",

volume = "123",

pages = "1772--1774",

journal = "Blood",

issn = "0006-4971",

publisher = "Elsevier B.V.",

number = "12",

}

TY - JOUR

T1 - Lymphocytosis and ibrutinib treatment of CLL

AU - Rossi, Davide

AU - Gaidano, Gianluca

PY - 2014/3/20

Y1 - 2014/3/20

N2 - In this issue of Blood, Woyach et al clarify that prolonged lymphocytosis is composed of biologically inert leukemic cells and does not anticipate poor outcome or relapse. Prolonged lymphocytosis may be perceived as a failure of chronic lymphocytic leukemia (CLL) treatment with ibrutinib.

AB - In this issue of Blood, Woyach et al clarify that prolonged lymphocytosis is composed of biologically inert leukemic cells and does not anticipate poor outcome or relapse. Prolonged lymphocytosis may be perceived as a failure of chronic lymphocytic leukemia (CLL) treatment with ibrutinib.

UR - http://www.scopus.com/inward/record.url?scp=84897514011&partnerID=8YFLogxK

U2 - 10.1182/blood-2014-01-549493

DO - 10.1182/blood-2014-01-549493

M3 - Comment/debate

SN - 0006-4971

VL - 123

SP - 1772

EP - 1774

JO - Blood

JF - Blood

IS - 12

ER -

Lymphocytosis and ibrutinib treatment of CLL

Abstract

Accesso al documento

Altri file e collegamenti

Fingerprint

Cita questo